Reinaldo Diaz
Director/Board Member chez LEXEO THERAPEUTICS, INC.
Fortune : - $ au 31/03/2024
Profil
Reinaldo M.
Diaz is the founder of Diaz & Altschul Capital Management LLC, which was founded in 1996.
He held the title of Managing Partner from 1996 to 2006.
Mr. Diaz currently holds the position of Chief Executive Officer at Opna Bio SA. He is also the Lead Independent Director at Inozyme Pharma, Inc. since 2023, Independent Director at Lexeo Therapeutics, Inc. since 2022, Managing Director at DA Advisors LLC since 2005, Venture Partner at Longitude Capital Management Co LLC since 2015, and Board Member at CrownWheel Partners LLC.
Additionally, he serves as the Chief Business Officer at Opna Immuno-Oncology SA. Mr. Diaz has previously worked as a Director at Valentis, Inc., Director at Haemacure Corp.
from 2008 to 2013, Managing Director at Schroder Wertheim & Co., Inc. from 1993 to 1996, Managing Director at Celtic Pharma Management LP from 2006 to 2011, Managing Director at Auven Therapeutics Management LLLP from 2008 to 2018, and Managing Director at China Telecom (Americas) Corp.
from 2007 to 2018.
He also served as President at PaineWebber, Inc. from 1981 to 1993.
Mr. Diaz obtained his undergraduate degree from Harvard University in 1977 and his MBA from Harvard Business School in 1981.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
INOZYME PHARMA, INC.
-.--% | 13/06/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
Postes actifs de Reinaldo Diaz
| Sociétés | Poste | Début |
|---|---|---|
| INOZYME PHARMA, INC. | Director/Board Member | 01/01/2017 |
| LEXEO THERAPEUTICS, INC. | Director/Board Member | 01/02/2022 |
Longitude Capital Management Co LLC
 Longitude Capital Management Co LLC Investment ManagersFinance Longitude Capital Management Co LLC (Longitude Capital) is a venture capital firm founded in 2006 by Juliet Trammenoms Bakker, Patrick Enright, David Hirsch and Marc-Henri Galletti. The firm is headquartered in Menlo Park, California. | Private Equity Investor | 01/11/2015 |
Opna Immuno-Oncology SA
 Opna Immuno-Oncology SA BiotechnologyHealth Technology Opna Immuno-Oncology SA is a Swiss biotechnology company that focuses on researching and developing biotechnology products. The private company is based in Saint-Sulpice, Switzerland. | Corporate Officer/Principal | - |
CrownWheel Partners LLC
 CrownWheel Partners LLC Financial ConglomeratesFinance CrownWheel Partners LLC engages in the provision of structure financing solutions with healthcare companies, academic institutions, and inventors. It focuses on the monetization of royalty streams, revenue participation, and purchase of structured debt and equity. The company was founded by Sandip K. Agarwala in 2013 and is headquartered in Greenwich, CT. | Director/Board Member | - |
| DA Advisors LLC | Private Equity Investor | 01/01/2005 |
Opna Bio SA
 Opna Bio SA Pharmaceuticals: GenericHealth Technology Opna Bio is a clinical-stage biopharmaceutical company located in the US that focuses on discovering and developing novel oncology therapeutics. Opna's lead clinical compound, opn-2853, a bromo and extra terminal (bet) domain inhibitor, is currently in a phase 1/2 trial with ruxolitinib (jakafi®) in myelofibrosis, a chronic bone marrow disorder. The American company's team has a proven track record of scientific expertise and commercial value creation, having advanced multiple FDA-approved drugs to market. The company has a broad portfolio that targets multiple drivers of cancer, including a novel oncology discovery program focused on the fragile-x mental retardation protein (fmrp) and a diversified pipeline of validated oncology assets acquired from plexxikon. | Chief Executive Officer | - |
Anciens postes connus de Reinaldo Diaz
| Sociétés | Poste | Fin |
|---|---|---|
China Telecom (Americas) Corp.
 China Telecom (Americas) Corp. Specialty TelecommunicationsCommunications China Telecom (Americas) Corp. is a private carrier and leading provider of communications and IT solutions for multinational enterprises and service providers in the Americas. The private company is based in Herndon, VA. China Telecom (Americas has offices in multiple locations throughout the Americas and is ultimately controlled by the Government of China. Founded in 2000, the company serves as a bridge to China and provides sales and support personnel across the Americas who are equipped with the necessary market expertise to successfully navigate local regulations, languages, and technical specifications to deploy IT solutions faster. | Private Equity Investor | 31/12/2018 |
Auven Therapeutics Management LLLP
 Auven Therapeutics Management LLLP Investment ManagersFinance Founded in 2007 by Stephen Evans-Freke and Peter Corr, Auven Therapeutics Management LLLP is a global private equity firm located in St. Thomas, Virgin Islands. They also have operations in New York City and Europe. The firm was formerly known as Celtic Therapeutics Management, which was the successor firm to Celtic Pharma Management LP. | Private Equity Investor | - |
| ░░░░░░░░░ ░░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░░░░ ░░░░░░░░░░ ░░ | ░░░░░░░ ░░░░░░ ░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░ ░░░░░ ░░░░░░░░ ░░░░░░░ ░░░░░░░░░░ ░░░ | ░░░░░░░ | ░░░░░░░░░░ |
Formation de Reinaldo Diaz
| Harvard University | Undergraduate Degree |
| Harvard Business School | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| INOZYME PHARMA, INC. | Health Technology |
| LEXEO THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 13 |
|---|---|
Valentis, Inc.
 Valentis, Inc. Pharmaceuticals: MajorHealth Technology Valentis lead drug candidate, Deltavasc, may treat peripheral arterial and ischemic heart disease with a gene that spurs new blood vessels to form (a process known as angiogenesis). In early stages of development are DNA vaccines for HIV, hepatitis C, and other viral infections. Another drug candidate, eNOS, could prevent tissue rejection in transplant recipients. The company licenses its technology -- include the GeneSwitch platform, which can turn off or on gene therapies -- to other drugmakers. These licensees include Genzyme, Pfizer, and GlaxoSmithKline. | Health Technology |
Haemacure Corp.
 Haemacure Corp. Industrial SpecialtiesProcess Industries Haemacure Corp. is engaged in the development, marketing and sales of surgical sealants and related medical devices. Its primary product is a fibrin sealant, a tissue sealant comprised of fibrinogen and thrombin extracted from human plasma. The fibrin sealant is used in surgical procedures to arrest bleeding and as an adjunct to wound healing. It was founded on August 19, 1991 and is headquartered in Montreal, Canada. | Process Industries |
Diaz & Altschul Capital Management LLC
 Diaz & Altschul Capital Management LLC Investment ManagersFinance Founded in 1992, Diaz & Altschul Capital Management LLC is a New York City-based hedge fund company. They manage the Delta Opportunity Fund LLC | Finance |
| PaineWebber, Inc. | Finance |
| Schroder Wertheim & Co., Inc. | Finance |
| DA Advisors LLC | |
Celtic Pharma Management LP
 Celtic Pharma Management LP Investment ManagersFinance Celtic Pharma Management LP is a private equity firm founded by Stephen Evans Freke and John Mayo in 2004. The firm headquartered in Bermuda. | Finance |
Longitude Capital Management Co LLC
Longitude Capital Management Co LLC Investment ManagersFinance Longitude Capital Management Co LLC (Longitude Capital) is a venture capital firm founded in 2006 by Juliet Trammenoms Bakker, Patrick Enright, David Hirsch and Marc-Henri Galletti. The firm is headquartered in Menlo Park, California. | Finance |
Auven Therapeutics Management LLLP
Auven Therapeutics Management LLLP Investment ManagersFinance Founded in 2007 by Stephen Evans-Freke and Peter Corr, Auven Therapeutics Management LLLP is a global private equity firm located in St. Thomas, Virgin Islands. They also have operations in New York City and Europe. The firm was formerly known as Celtic Therapeutics Management, which was the successor firm to Celtic Pharma Management LP. | Finance |
CrownWheel Partners LLC
CrownWheel Partners LLC Financial ConglomeratesFinance CrownWheel Partners LLC engages in the provision of structure financing solutions with healthcare companies, academic institutions, and inventors. It focuses on the monetization of royalty streams, revenue participation, and purchase of structured debt and equity. The company was founded by Sandip K. Agarwala in 2013 and is headquartered in Greenwich, CT. | Finance |
China Telecom (Americas) Corp.
China Telecom (Americas) Corp. Specialty TelecommunicationsCommunications China Telecom (Americas) Corp. is a private carrier and leading provider of communications and IT solutions for multinational enterprises and service providers in the Americas. The private company is based in Herndon, VA. China Telecom (Americas has offices in multiple locations throughout the Americas and is ultimately controlled by the Government of China. Founded in 2000, the company serves as a bridge to China and provides sales and support personnel across the Americas who are equipped with the necessary market expertise to successfully navigate local regulations, languages, and technical specifications to deploy IT solutions faster. | Communications |
Opna Immuno-Oncology SA
Opna Immuno-Oncology SA BiotechnologyHealth Technology Opna Immuno-Oncology SA is a Swiss biotechnology company that focuses on researching and developing biotechnology products. The private company is based in Saint-Sulpice, Switzerland. | Health Technology |
Opna Bio SA
Opna Bio SA Pharmaceuticals: GenericHealth Technology Opna Bio is a clinical-stage biopharmaceutical company located in the US that focuses on discovering and developing novel oncology therapeutics. Opna's lead clinical compound, opn-2853, a bromo and extra terminal (bet) domain inhibitor, is currently in a phase 1/2 trial with ruxolitinib (jakafi®) in myelofibrosis, a chronic bone marrow disorder. The American company's team has a proven track record of scientific expertise and commercial value creation, having advanced multiple FDA-approved drugs to market. The company has a broad portfolio that targets multiple drivers of cancer, including a novel oncology discovery program focused on the fragile-x mental retardation protein (fmrp) and a diversified pipeline of validated oncology assets acquired from plexxikon. | Health Technology |
